Adavosertib

SKU: orb1306538

Description

Adavosertib (MK-1775) is a potent and selective Wee1 kinase inhibitor (IC50=5.2 nM) that induces cell cycle arrest and inhibits proliferation. It is widely used in cancer research, particularly in studies of DNA damage response, and has demonstrated antitumor efficacy in both in vitro and in vivo models.

Research Area

Cell Biology

Key Properties

• CAS Number: 955365-80-7
• MW: 500.6
• Purity: 99.86%
• Formula: C₂₇H₃₂N₈O₂
• SMILES: C(C=C)N1N(C=2C(C1=O)=CN=C(NC3=CC=C(C=C3)N4CCN(C)CC4)N2)C=5N=C(C(C)(C)O)C=CC5
• Target: Wee1
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:7.4 mg/mL (14.78 mM);DMSO:240 mg/mL (479.42 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  NCI-H1299 cells:0.2837 nM|PC3 cells:8 μM|BT-549 cells:0.49 μM|MDA-MB-231 cells:0.26 μM|LNCaP cells:0.5 μM|MM.1S cells:0.31 μM|HEK293T cells:0.29 μM|Wee1:5.2 nM (cell free)|MCF-7 cells:1.1 μM|MV-4-11 cells:95 nM|NCI-H23 cells:122 nM|A427 cells:78 nM|Daoy cells:150 nM
• In Vivo:
  Gemcitabine was administered to nude rats bearing WiDr (human colorectal) tumors at a dose of 50 mg/kg (i.v., bolus). Twenty-four hours later, MK-1775 was p.o. administered at a dose of 5, 10, or 20 mg/kg. Gemcitabine alone only moderately inhibited tumor growth. Cotreatment with MK-1775 significantly enhanced the antitumor effects in a dose-dependent manner and was well tolerated . MK-1775 also significantly enhanced the antitumor efficacy of radiation in vivo as shown in tumor growth delay studies, again for p53-defective tumors .
• In Vitro:
  MK-1775 (Adavosertib) inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells. MK-1775 abrogates G(2) DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells . Nanomolar concentrations of MK-1775 radiosensitized p53-defective human lung, breast, and prostate cancer cells but not similar lines with wild-type p53. Consistent with its ability to radiosensitize, MK-1775 abrogated the radiation-induced G block in p53-defective cells but not in p53 wild-type lines .
• Cell Research:
  Tumor cells were cultured in 96-well plates and incubated with DNA-damaging agents for 24 h, then with MK-1775 and nocodazole for additional 8 h. For p-CDC2Y15 assay, cells were lysed and subjected in a colorimetric ELISA to determine the amounts of p-CDC2Y15 (1:100) and total CDC2 (1:200). For phospho-histone H3 (pHH3), cells were fixed with methanol, stained with anti-pHH3 specific antibody and bound antibody was stained with Alexa Fluor 488 goat anti-rabbit antibody. Images were acquired with an INCell Analyzer 1000 .
• Animal Research:
  Subcutaneous xenograft tumors were formed by injection of the human cancer cell lines in the hind flank of immunodeficient nude rats (F344/NJcl-rnu). To facilitate tumor formation, cells were injected in medium containing Matrigel, a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm mouse sarcoma. Gemcitabine, carboplatin, and cisplatin were dissolved or diluted in saline and were dosed i.v. MK-1775 was prepared in a vehicle of 0.5% methylcellulose solution and was dosed p.o. 24 h after dosing DNA-damaging agents. For efficacy studies, tumor volumes were measured with a caliper every 3 d and body weights were determined each weekday. Statistical analysis was done using repeated-measure ANOVA followed by Dunnett's test for relative tumor volume. T/C (%) was calculated as (ΔT/ΔC) × 100 if ΔT > 0 or (ΔT/TI) × 100 if ΔT < 0. ΔT was the change in mean tumor volume to the initial tumor volume for the treatment group, and ΔC was the change in mean tumor volume to the initial tumor volume for the vehicle control group. Ti was the initial tumor volume of the treatment group .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Adavosertib, Adavosertib (MK-1775), AZD 1775, AZD1775, AZD-1775, MK1775, MK-1775, MK 1775, inhibit, Inhibitor, Wee1

Compound Identifiers

PubChem CID

24856436